It’s time to think active hemostasis

Many patients have comorbidities or use medications that can compromise their coagulation status

1 in 7

adults have renal failure⁴

30%

of the US population use low-dose aspirin for CVD prevention⁵

1 in 50

adults have liver disease⁶

1 in 3

adults will be diagnosed with cancer in their lifetime⁷

Unlike passive hemostats, active hemostats are able to control a wider range of bleeding, from mild to severe⁹

Hemostats achieved
within 10 minutes*

Passive

Active

Bleeding Severity

Learn more about the first surgeon validated and FDA accepted intraoperative bleeding scale. Click here.

*Based on preclinical data. Results may not correlate to performance in humans.

Active hemostatic products are available as flowables, fibrin sealants or advanced patches

Active hemostatic products

Flowables(thrombin + gelatin)
Fibrin sealant
Stand-alone thrombin
Advanced patcheswith PEG or fibrin sealants

Passive hemostatic products

Oxidized Cellulose
Collagens
Powders
Gelatin Sponges
Polysaccharide Spheres

Use of an active hemostat could significantly improve clinical outcomes and help hospitals save money^{10, 12}

Compared with a passive hemostat, use of an active hemostat can result in:

6x

faster hemostasisin mild-to-moderate bleeding, regardless of
coagulation status and initial bleeding rate^9*

*Preclinical data. Results may not correlate to performance in humans.

24 mins

shorter operative time in CV procedures¹⁰

53%

lower transfusion rate in CV procedures¹⁰

67%

lower revision rate in CV procedures¹⁰

38%

reduction in minor complications
in CV procedures¹⁰

$5.38m

annual net savings with exclusive use of active
hemostats in CV procedures¹²

Based on Matthew’s notes, what would be the most appropriate hemostasis strategy?

(Select Active or Passive below)

Name: Matthew B.

Age: 68 years old

Procedure: Coronary Artery Bypass

Notes and Observations:

- History of Renal failure
- On NOAC therapy for A Fib
- Dual Antiplatelet Therapy
- Daily fish oil supplement

Hemostatic agent

Active Passive

It’s time to think about your hemostasis strategy

Please share your views with us!*

Do you agree that patient coagulation should influence your hemostat selection?

Yes No

Would you use an active hemostat as your first line adjunctive hemostat?

Yes No

*All insights and personal data will be treated in the strictest confidence

Learn more

Access key articles on bleeding complications and topical hemostats

The Use of Topical Hemostatic Agents in Cardiothoracic Surgery

Evidence-based recommendations for the use of topical hemostatic agents in cardiothoracic surgery.

Prospective, Randomized Clinical Trial of the FloSeal Matrix Sealant in Cardiac Surgery

Prospective randomized clinical study comparing an active hemostate (FLOSEAL) to a passive hemostat (SURGICEL NU-KNIT or GELFOAM) in cardiac and thoracic aortic surgery involving 451 patients.

Inefficiencies in Blood Utilization: Opportunities for Improved Outcomes and Policy Action

Summary of meeting between Baxter and experts on key trends in bleeding management, and the need for education on bleeding management.

Impact of Bleeding-related Complications and/or Blood Product Transfusions on Hospital Costs in Inpatient Surgical Patients

Retrospective analysis of bleeding complications during 1.6 million surgeries across multiple specialties performed in the US

Hospital Economic Impact From Hemostatic Matrix Usage in Cardiac Surgery

Cost consequence framework applied to results from a clinical trial comparing active and passive hemostats in 209 patients undergoing cardiac surgery

Access key articles on bleeding complications and topical hemostats

The Use of Topical Hemostatic Agents in Cardiothoracic Surgery

Evidence-based recommendations for the use of topical hemostatic agents in cardiothoracic surgery.

Prospective, Randomized Clinical Trial of the FloSeal Matrix Sealant in Cardiac Surgery

Prospective randomized clinical study comparing an active hemostate (FLOSEAL) to a passive hemostat (SURGICEL NU-KNIT or GELFOAM) in cardiac and thoracic aortic surgery involving 451 patients.

Inefficiencies in Blood Utilization: Opportunities for Improved Outcomes and Policy Action

Summary of meeting between Baxter and experts on key trends in bleeding management, and the need for education on bleeding management.

Impact of Bleeding-related Complications and/or Blood Product Transfusions on Hospital Costs in Inpatient Surgical Patients

Retrospective analysis of bleeding complications during 1.6 million surgeries across multiple specialties performed in the US

Hospital Economic Impact From Hemostatic Matrix Usage in Cardiac Surgery

Cost consequence framework applied to results from a clinical trial comparing active and passive hemostats in 209 patients undergoing cardiac surgery

References

1. Stokes ME, et al. BMC Health Services Research 2011;11:135; 2. Salive ME. Epidemiol Rev 2013;35:75–83; 3. Mather M, et al. Aging in the United States. Population Bulletin 70, 2015. Available at: https://www.prb.org/wp-content/uploads/2016/01/aging-us-population-bulletin-1.pdf (accessed January 2020); 4. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System. Available at: https://nccd.cdc.gov/ckd/default.aspx (Accessed January 2020); 5. Stuntz M, et al. Prev Med Rep. 2017;5:183–186; 6. Centers for Disease Control and Prevention. Chronic Liver Disease and Cirrhosis. Available at: https://www.cdc.gov/nchs/fastats/liver-disease.htm (Accessed January 2020); 7. American Cancer Society. Facts & Figures 2019: US Cancer Death Rate has Dropped 27% in 25 Years, Jan 2019. Available at: https://www.cancer.org/latest-news/facts-and-figures-2019.html (Accessed January 2020); 8. Corral M, et al. Clinicoecon Outcomes Res 2015;7:409–21; 9. Slezak P, et al. J Invest Surg 2020; ePub ahead of print; 10. Nasso G, et al. Ann Thorac Surg 2009;88:1520–6; 11. Bracey A, et al. Ann Thorac Surg 2017;104:353–60; 12. Tackett SM, et al. J Med Econ 2014;17:670–6.


	A Active	P Passive
Function independently of the patient’s ability to generate clotting factors to achieve hemostasis
Effective regardless of coagulation status
Effective across a wide range of bleeding

1 in 3 patients experience bleeding-related complications during surgery that impact recovery1

What would your active hemostasis strategy be for Matthew?

What would your active hemostasis strategy be for Lanelle?

What would your active hemostasis strategy be for Anna?

As the population ages, surgical complexity increases due to accumulation of comorbidities2

At least 62% of adults aged 65-74 have multiple comorbidities2

Prevalence of multiple comorbidities increases to >80% in adults aged ≥852

Many patients have comorbidities or use medications that can compromise their coagulation status

1 in 7

30%

1 in 50

1 in 3

A compromised coagulation status increases the risk of intraoperative bleeding complications8

Active adjunctive hemostats are more effective than passive hemostats9-11

Unlike passive hemostats, active hemostats are able to control a wider range of bleeding, from mild to severe9

Learn more about the first surgeon validated and FDA accepted intraoperative bleeding scale. Click here.

Active hemostatic products are available as flowables, fibrin sealants or advanced patches

Use of an active hemostat could significantly improve clinical outcomes and help hospitals save money10, 12

Compared with a passive hemostat, use of an active hemostat can result in:

6x

faster hemostasisin mild-to-moderate bleeding, regardless of coagulation status and initial bleeding rate9*

24 mins

shorter operative time in CV procedures10

53%

lower transfusion rate in CV procedures10

67%

lower revision rate in CV procedures10

38%